Literature DB >> 12937314

Early renal insufficiency and hospitalized heart disease after renal transplantation in the era of modern immunosuppression.

Kevin C Abbott1, Christina M Yuan, Allen J Taylor, David F Cruess, Lawrence Y C Agodoa.   

Abstract

Renal insufficiency has been identified as a risk factor for graft loss and death after renal transplantation but has not been consistently linked to early, nonfatal, hospitalized heart disease (HHD). With the United States Renal Data System database, 29,597 patients who received a kidney transplant between January 1, 1996, and July 31, 2000, with Medicare as the primary payer, and were monitored until December 31, 2000, were studied. Cox proportional-hazards regression models were used to calculate the association of recipient estimated GFR (eGFR) at 1 yr after renal transplantation, as determined with the Modification of Diet in Renal Disease formula, with hospitalization for treatment of acute coronary syndromes (ACS) (International Classification of Diseases, version 9, code 410.x or 411.x) or congestive heart failure (CHF) (code 428.x) 1 to 3 yr after renal transplantation. Rates of ACS and CHF were 2.2 and 4.9%, respectively, for patients with eGFR of <44.8 ml/min per 1.73 m(2), compared with 1.2 and 1.4% for patients with eGFR of >69.7 ml/min per 1.73 m(2). Reduced eGFR (<44.8 ml/min per 1.73 m(2), compared with >69.7 ml/min per 1.73 m(2)) at the end of the first 1 yr after transplantation was independently associated with increased risks of both ACS (adjusted hazard ratio, 2.16; 95% confidence interval, 1.39 to 3.35) and CHF (adjusted hazard ratio, 2.95; 95% confidence interval, 2.24 to 3.90). It was concluded that early renal insufficiency (approximately stage 3 chronic kidney disease) was associated with higher rates of HHD 1 to 3 yr after kidney transplantation. Preservation of renal function after renal transplantation may reduce the rates of HHD, and renal transplant recipients with reduced eGFR should be considered at high risk of developing cardiovascular disease.

Entities:  

Mesh:

Year:  2003        PMID: 12937314     DOI: 10.1097/01.asn.0000083008.25305.67

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  11 in total

Review 1.  Cardiovascular risk factors following renal transplant.

Authors:  Jill Neale; Alice C Smith
Journal:  World J Transplant       Date:  2015-12-24

2.  Obesity and cardiac risk after kidney transplantation: experience at one center and comprehensive literature review.

Authors:  Krista L Lentine; Lisa A Rocca-Rey; Giuliana Bacchi; Nadia Wasi; Leslie Schmitz; Paolo R Salvalaggio; Kevin C Abbott; Mark A Schnitzler; Luca Neri; Daniel C Brennan
Journal:  Transplantation       Date:  2008-07-27       Impact factor: 4.939

Review 3.  Everolimus in kidney transplant recipients at high cardiovascular risk: a narrative review.

Authors:  Ernesto Paoletti; Franco Citterio; Alberto Corsini; Luciano Potena; Paolo Rigotti; Silvio Sandrini; Elisabetta Bussalino; Giovanni Stallone
Journal:  J Nephrol       Date:  2019-04-27       Impact factor: 3.902

4.  Urinary Markers of Fibrosis and Risk of Cardiovascular Events and Death in Kidney Transplant Recipients: The FAVORIT Trial.

Authors:  M Park; R Katz; M G Shlipak; D Weiner; R Tracy; V Jotwani; J Hughes-Austin; F Gabbai; C Y Hsu; M Pfeffer; N Bansal; A Bostom; O Gutierrez; M Sarnak; A Levey; J H Ix
Journal:  Am J Transplant       Date:  2017-04-26       Impact factor: 8.086

5.  Filtration Markers, Cardiovascular Disease, Mortality, and Kidney Outcomes in Stable Kidney Transplant Recipients: The FAVORIT Trial.

Authors:  M C Foster; D E Weiner; A G Bostom; M A Carpenter; L A Inker; P Jarolim; A A Joseph; J W Kusek; T Pesavento; M A Pfeffer; M Rao; S D Solomon; A S Levey
Journal:  Am J Transplant       Date:  2017-03-30       Impact factor: 8.086

6.  Five-year safety and efficacy of belatacept in renal transplantation.

Authors:  Flavio Vincenti; Gilles Blancho; Antoine Durrbach; Peter Friend; Josep Grinyo; Philip F Halloran; Jurgen Klempnauer; Philippe Lang; Christian P Larsen; Ferdinand Mühlbacher; Björn Nashan; Jean-Paul Soulillou; Yves Vanrenterghem; Thomas Wekerle; Mamta Agarwal; Sheila Gujrathi; Jinshan Shen; Rebecca Shi; Robert Townsend; Bernard Charpentier
Journal:  J Am Soc Nephrol       Date:  2010-07-15       Impact factor: 10.121

7.  The impact of kidney transplantation on heart failure risk varies with candidate body mass index.

Authors:  Krista L Lentine; Huiling Xiao; Daniel C Brennan; Mark A Schnitzler; Todd C Villines; Kevin C Abbott; David Axelrod; Jon J Snyder; Paul J Hauptman
Journal:  Am Heart J       Date:  2009-12       Impact factor: 4.749

8.  Variations in the risk for cerebrovascular events after kidney transplant compared with experience on the waiting list and after graft failure.

Authors:  Krista L Lentine; Lisa A Rocca Rey; Swathy Kolli; Giuliana Bacchi; Mark A Schnitzler; Kevin C Abbott; Huiling Xiao; Daniel C Brennan
Journal:  Clin J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 8.237

Review 9.  Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk.

Authors:  Johannes M M Boots; Maarten H L Christiaans; Johannes P van Hooff
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Cardiac evaluation before kidney transplantation: a practice patterns analysis in Medicare-insured dialysis patients.

Authors:  Krista L Lentine; Mark A Schnitzler; Daniel C Brennan; Jon J Snyder; Paul J Hauptman; Kevin C Abbott; David Axelrod; Paolo R Salvalaggio; Bertram Kasiske
Journal:  Clin J Am Soc Nephrol       Date:  2008-04-16       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.